XWXiaodong Wang

Xiaodong Wang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Xiaodong Wang has a total of 17 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Materials Control of Nitric Oxide in Cancer Immunotherapy

    by Xiaodong Wang, Qianqian Wang, Siran Wu, Wei Gao, Songjiang He, Bingwen Zou, Zheng Li

    Nitric oxide (NO) can suppress antitumor immunity, support tumor adaptation, or promote immune‐mediated killing, making its therapeutic manipulation highly dependent on exposure. This Review examines how materials control NO source, localization, release kinetics, and chemical fate in cancer immunotherapy, with particular attention to immune checkpoint blockade (ICB). We analyze polymeric donors, nanocarriers, injectable depots, and strategies for restricting endogenous NO production, linking their physicochemical properties to target exposure and immune function. Evidence from checkpoint‐treated models is distinguished from mechanisms established with other therapies and from human associations. Comparative analyses separate donor capacity from measured NO exposure, carrier accumulation from cellular delivery, and distant‐tumor control from demonstrated immune memory. Four overlapping endogenous contexts, comprising tumor adaptation, myeloid suppression, vascular dysfunction, and inflammatory effector activity, guide intervention design without constituting validated patient categories. We identify testable predictions concerning cellular selectivity, release kinetics, and spatial pharmacodynamic responses. Translation requires measurements that connect material behavior to a defined NO‐dependent process while demonstrating preservation of beneficial endothelial and immune functions. This framework provides a basis for evaluating when localized NO delivery or selective inhibition may support ICB, while recognizing the limits of current preclinical and clinical evidence.

  • Radiation-induced cell-death states in cancer: Toward biomarker-guided radioimmunotherapy

    by Xiaodong Wang, Wei Gao, Qianqian Wang, Songjiang He, Bingwen Zou

  • Open Access

    Cancer-associated fibroblast–tumor organoid models of therapy resistance: mechanisms, materials, and translational potential

    by Xiaodong Wang, Qianqian Wang, Junjie Wang, Gouping Ding, Yiping Huang, Yeqian Feng, Bingwen Zou

  • Open Access

    Immune Evasion in Ovarian Cancer Peritoneal Metastasis: Mechanisms and Biomarker‐Guided Therapeutic Matching

    by Xiaodong Wang, Junjie Wang, Di Xiong, Songli Cui, Qianqian Wang, Yiping Huang, Gouping Ding, Yixuan Tang, Yeqian Feng

    Ovarian cancer peritoneal metastasis remains a major cause of recurrence and death despite advances in cytoreductive surgery, platinum‐based chemotherapy, PARP inhibition, and immune checkpoint blockade. The limited activity of immunotherapy in this setting reflects layered immune resistance shaped by impaired antigen visibility, redundant inhibitory receptor networks, suppressive myeloid and regulatory circuits, and metabolic‐epigenetic constraints within ascites and multicellular spheroids. These compartment‐specific features distinguish peritoneal disease from anatomically confined tumors and help explain why systemic immune reinvigoration alone rarely produces durable benefit. Here, we synthesize current evidence on the mechanisms that govern immune escape in ovarian cancer peritoneal dissemination, with emphasis on antigen presentation defects, checkpoint‐driven T‐cell exhaustion, anti‐phagocytic signaling, soluble suppressive mediators, and metabolic remodeling of the ascites microenvironment. We further examine how DNA damage response states intersect with innate immune sensing and discuss the translational implications of homologous recombination deficiency for combination treatment design. Finally, we propose a biomarker‐guided framework that links antigen‐presentation competence, immune engagement, dominant suppressive axes, and ascites‐specific biology to rational therapeutic matching. This mechanism‐centered view supports more precise trial design and provides a roadmap for combination immunotherapy in advanced ovarian cancer.

  • Open Access

    Artificial Intelligence–Enabled Multi-Omics for Predicting Immune Checkpoint Inhibitor Response and Resistance

    by Xiaodong Wang, Jing He, Gouping Ding, Yixuan Tang, Qianqian Wang

    Immune checkpoint inhibitors (ICIs) have reshaped oncology, yet overall response rates remain modest and resistance is common, driven by tumor heterogeneity and evolving tumor–immune crosstalk. Established biomarkers (PD-L1, tumor mutational burden, microsatellite instability) provide incomplete prediction. Multi-omics profiling across genomic, transcriptomic, proteomic, epigenomic, metabolomic and microbiomic layers offers a systems-level view of malignant and immune states, uncovering determinants of ICI efficacy such as lineage plasticity, stromal remodeling, immunometabolic reprogramming and microbiome-associated immune modulation. Artificial intelligence (AI) is uniquely positioned to fuse these heterogeneous data, learn non-linear cross-layer signatures, and enable interpretable predictions using approaches such as SHAP and Grad-CAM. Representative models link routine histology or imaging to molecular phenotypes, stratify patients beyond single biomarkers, and may nominate rational combinations that target oncogenic pathways, lactate-driven immune suppression, or the gut microbiome. In this narrative review, we synthesize recent AI–multi-omics advances for response modeling, immune-relevant tumor subtyping, and clinical translation, including radiomics/pathomics integration and liquid-biopsy–based monitoring, as well as emerging applications in toxicity risk prediction. We also discuss barriers to implementation—platform heterogeneity, limited prospective validation, bias, interpretability and cost—and outline future directions, including single-cell and spatial multi-omics integration, federated learning and generative modeling to improve robustness and equity of precision immunotherapy.


  • Open Access

    Artificial intelligence in multidisciplinary tumor boards enhancing decision making and clinical outcomes in oncology

    by Xiaodong Wang, Qianqian Wang, Gouping Ding, Junjie Wang, Yixuan Tang, Yeqian Feng